Comparison of Two Phase II Trials of Neoadjuvant Temozolomide Followed with Concomitant and Adjuvant Temozolomide and Hypofractionated Accelerated Radiotherapy with or without Metformin in Patients with Newly Diagnosed Glioblastoma

被引：0
|
作者：
Shenouda, G. [1 ]
Petrecca, K. [2 ]
Abdulkarim, B. S. [3 ]
Owen, S. [1 ]
Panet-Raymond, V. [3 ]
Diaz, R. [4 ]
Guiot, M. C. [5 ]
Carvalho, T. [6 ]
Charbonneau, M. [1 ]
Hall, J. [7 ]
Souhami, L.
机构：
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] McGill Univ, Neurosurg, Montreal, PQ, Canada
[3] McGill Univ, Ctr Hlth, Dept Radiat Oncol, Montreal, PQ, Canada
[4] Montreal Neurol Hosp, Montreal, PQ, Canada
[5] Montreal Neurol Inst Hosp, Dept Pathol, Montreal, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Montreal Neurol Hosp, Montreal, PQ, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [31] A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
    Rosenfeld, M. R.
    Chamberlain, M. C.
    Grossman, S. A.
    Peereboom, D. M.
    Lesser, G. J.
    Batchelor, T. T.
    Desideri, S.
    Salazar, A. M.
    Ye, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis
    Guo, Longbin
    Li, Xuanzi
    Chen, Yulei
    Liu, Rongping
    Ren, Chen
    Du, Shasha
    CANCER RADIOTHERAPIE, 2021, 25 (02): : 182 - 190
  • [33] Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
    Carlson, Julie A.
    Reddy, Krishna
    Gaspar, Laurie E.
    Ney, Douglas
    Kavanagh, Brian D.
    Damek, Denise
    Lillehei, Kevin
    Chen, Changhu
    JOURNAL OF NEURO-ONCOLOGY, 2015, 123 (02) : 251 - 257
  • [34] A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis
    Shenouda, G.
    Souhami, L.
    Petrecca, K.
    Owen, S.
    Panet-Raymond, V.
    Carvalho, T.
    Guiot, M. C.
    Abdulkarim, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S48 - S49
  • [35] Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
    Julie A. Carlson
    Krishna Reddy
    Laurie E. Gaspar
    Douglas Ney
    Brian D. Kavanagh
    Denise Damek
    Kevin Lillehei
    Changhu Chen
    Journal of Neuro-Oncology, 2015, 123 : 251 - 257
  • [36] A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients
    Pan, Edward
    Mitchell, Susan B.
    Tsai, Jerry S.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (03) : 353 - 357
  • [37] A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients
    Edward Pan
    Susan B. Mitchell
    Jerry S. Tsai
    Journal of Neuro-Oncology, 2008, 88 : 353 - 357
  • [38] Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
    Saran, Frank
    Welsh, Liam
    James, Allan
    McBain, Catherine
    Gattamaneni, Rao
    Jefferies, Sarah
    Harris, Fiona
    Pemberton, Karine
    Schaible, Jennifer
    Bender, Shaun
    Cseh, Agnieszka
    Brada, Michael
    JOURNAL OF NEURO-ONCOLOGY, 2021, 155 (03) : 307 - 317
  • [39] Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
    Frank Saran
    Liam Welsh
    Allan James
    Catherine McBain
    Rao Gattamaneni
    Sarah Jefferies
    Fiona Harris
    Karine Pemberton
    Jennifer Schaible
    Shaun Bender
    Agnieszka Cseh
    Michael Brada
    Journal of Neuro-Oncology, 2021, 155 : 307 - 317
  • [40] RANDOMIZED PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB AND IRINOTECAN VERSUS BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN NEWLY DIAGNOSED PRIMARY GLIOBLASTOMA MULTIFORME
    Hofland, Kenneth F.
    Hansen, Steinbjorn
    Sorensen, Morten
    Schultz, Henrik
    Muhic, Aida
    Engelholm, Silke
    Ask, Anders
    Kristiansen, Charlotte
    Thomsen, Carsten
    Poulsen, Hans S.
    Lassen, Ulrik N.
    NEURO-ONCOLOGY, 2011, 13 : 51 - 52
12345